362 related articles for article (PubMed ID: 10493777)
1. Aldose and aldehyde reductases: structure-function studies on the coenzyme and inhibitor-binding sites.
El-Kabbani O; Old SE; Ginell SL; Carper DA
Mol Vis; 1999 Sep; 5():20. PubMed ID: 10493777
[TBL] [Abstract][Full Text] [Related]
2. Structure of aldehyde reductase holoenzyme in complex with the potent aldose reductase inhibitor fidarestat: implications for inhibitor binding and selectivity.
El-Kabbani O; Carbone V; Darmanin C; Oka M; Mitschler A; Podjarny A; Schulze-Briese C; Chung RP
J Med Chem; 2005 Aug; 48(17):5536-42. PubMed ID: 16107153
[TBL] [Abstract][Full Text] [Related]
3. Structure of rat aldose reductase-like protein AKR1B14 holoenzyme: Probing the role of His269 in coenzyme binding by site-directed mutagenesis.
Sundaram K; Dhagat U; Endo S; Chung R; Matsunaga T; Hara A; El-Kabbani O
Bioorg Med Chem Lett; 2011 Jan; 21(2):801-4. PubMed ID: 21168333
[TBL] [Abstract][Full Text] [Related]
4. Kinetic and spectroscopic evidence for active site inhibition of human aldose reductase.
Nakano T; Petrash JM
Biochemistry; 1996 Aug; 35(34):11196-202. PubMed ID: 8780524
[TBL] [Abstract][Full Text] [Related]
5. Aldehyde reductase: the role of C-terminal residues in defining substrate and cofactor specificities.
Rees-Milton KJ; Jia Z; Green NC; Bhatia M; El-Kabbani O; Flynn TG
Arch Biochem Biophys; 1998 Jul; 355(2):137-44. PubMed ID: 9675019
[TBL] [Abstract][Full Text] [Related]
6. A 'specificity' pocket inferred from the crystal structures of the complexes of aldose reductase with the pharmaceutically important inhibitors tolrestat and sorbinil.
Urzhumtsev A; Tête-Favier F; Mitschler A; Barbanton J; Barth P; Urzhumtseva L; Biellmann JF; Podjarny A; Moras D
Structure; 1997 May; 5(5):601-12. PubMed ID: 9195881
[TBL] [Abstract][Full Text] [Related]
7. Factorizing selectivity determinants of inhibitor binding toward aldose and aldehyde reductases: structural and thermodynamic properties of the aldose reductase mutant Leu300Pro-fidarestat complex.
Petrova T; Steuber H; Hazemann I; Cousido-Siah A; Mitschler A; Chung R; Oka M; Klebe G; El-Kabbani O; Joachimiak A; Podjarny A
J Med Chem; 2005 Sep; 48(18):5659-65. PubMed ID: 16134934
[TBL] [Abstract][Full Text] [Related]
8. The C-terminal loop of aldehyde reductase determines the substrate and inhibitor specificity.
Barski OA; Gabbay KH; Bohren KM
Biochemistry; 1996 Nov; 35(45):14276-80. PubMed ID: 8916913
[TBL] [Abstract][Full Text] [Related]
9. Structural features of the aldose reductase and aldehyde reductase inhibitor-binding sites.
El-Kabbani O; Wilson DK; Petrash M; Quiocho FA
Mol Vis; 1998 Sep; 4():19. PubMed ID: 9756955
[TBL] [Abstract][Full Text] [Related]
10. Studies on the inhibitor-binding site of porcine aldehyde reductase: crystal structure of the holoenzyme-inhibitor ternary complex.
el-Kabbani O; Carper DA; McGowan MH; Devedjiev Y; Rees-Milton KJ; Flynn TG
Proteins; 1997 Oct; 29(2):186-92. PubMed ID: 9329083
[TBL] [Abstract][Full Text] [Related]
11. Probing flexibility and "induced-fit" phenomena in aldose reductase by comparative crystal structure analysis and molecular dynamics simulations.
Sotriffer CA; Krämer O; Klebe G
Proteins; 2004 Jul; 56(1):52-66. PubMed ID: 15162486
[TBL] [Abstract][Full Text] [Related]
12. High-resolution crystal structure of aldose reductase complexed with the novel sulfonyl-pyridazinone inhibitor exhibiting an alternative active site anchoring group.
Steuber H; Zentgraf M; Podjarny A; Heine A; Klebe G
J Mol Biol; 2006 Feb; 356(1):45-56. PubMed ID: 16337231
[TBL] [Abstract][Full Text] [Related]
13. Ultrahigh resolution drug design. II. Atomic resolution structures of human aldose reductase holoenzyme complexed with Fidarestat and Minalrestat: implications for the binding of cyclic imide inhibitors.
El-Kabbani O; Darmanin C; Schneider TR; Hazemann I; Ruiz F; Oka M; Joachimiak A; Schulze-Briese C; Tomizaki T; Mitschler A; Podjarny A
Proteins; 2004 Jun; 55(4):805-13. PubMed ID: 15146479
[TBL] [Abstract][Full Text] [Related]
14. Structure of aldehyde reductase in ternary complex with a 5-arylidene-2,4-thiazolidinedione aldose reductase inhibitor.
Carbone V; Giglio M; Chung R; Huyton T; Adams J; Maccari R; Ottana R; Hara A; El-Kabbani O
Eur J Med Chem; 2010 Mar; 45(3):1140-5. PubMed ID: 20036445
[TBL] [Abstract][Full Text] [Related]
15. X-ray structure of the V301L aldo-keto reductase 1B10 complexed with NADP(+) and the potent aldose reductase inhibitor fidarestat: implications for inhibitor binding and selectivity.
Ruiz FX; Cousido-Siah A; Mitschler A; Farrés J; Parés X; Podjarny A
Chem Biol Interact; 2013 Feb; 202(1-3):178-85. PubMed ID: 23295227
[TBL] [Abstract][Full Text] [Related]
16. Structure of human aldose reductase holoenzyme in complex with statil: an approach to structure-based inhibitor design of the enzyme.
El-Kabbani O; Ramsland P; Darmanin C; Chung RP; Podjarny A
Proteins; 2003 Feb; 50(2):230-8. PubMed ID: 12486717
[TBL] [Abstract][Full Text] [Related]
17. Mechanism of human aldehyde reductase: characterization of the active site pocket.
Barski OA; Gabbay KH; Grimshaw CE; Bohren KM
Biochemistry; 1995 Sep; 34(35):11264-75. PubMed ID: 7669785
[TBL] [Abstract][Full Text] [Related]
18. The alrestatin double-decker: binding of two inhibitor molecules to human aldose reductase reveals a new specificity determinant.
Harrison DH; Bohren KM; Petsko GA; Ringe D; Gabbay KH
Biochemistry; 1997 Dec; 36(51):16134-40. PubMed ID: 9405046
[TBL] [Abstract][Full Text] [Related]
19. Merging the binding sites of aldose and aldehyde reductase for detection of inhibitor selectivity-determining features.
Steuber H; Heine A; Podjarny A; Klebe G
J Mol Biol; 2008 Jun; 379(5):991-1016. PubMed ID: 18495158
[TBL] [Abstract][Full Text] [Related]
20. Aldose and aldehyde reductases: correlation of molecular modeling and mass spectrometric studies on the binding of inhibitors to the active site.
El-Kabbani O; Rogniaux H; Barth P; Chung RP; Fletcher EV; Van Dorsselaer A; Podjarny A
Proteins; 2000 Nov; 41(3):407-14. PubMed ID: 11025551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
